Abcam (ABCZF) EV-to-EBITDA : 67.72 (As of Apr. 26, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Abcam EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Abcam's enterprise value is $5,294.5 Mil. Abcam's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $78.2 Mil. Therefore, Abcam's EV-to-EBITDA for today is 67.72.

The historical rank and industry rank for Abcam's EV-to-EBITDA or its related term are showing as below:

ABCZF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.26 Med: 30.94 Max: 109
Current: 67.72

During the past 13 years, the highest EV-to-EBITDA of Abcam was 109.00. The lowest was 13.26. And the median was 30.94.

ABCZF's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.14 vs ABCZF: 67.72

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Abcam's stock price is $22.25. Abcam's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.015. Therefore, Abcam's PE Ratio for today is 1,483.33.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Abcam EV-to-EBITDA Historical Data

The historical data trend for Abcam's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abcam EV-to-EBITDA Chart

Abcam Annual Data

Trend

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec22

EV-to-EBITDA

Get a 7-Day Free Trial

27.89

30.33

41.77

70.82

70.33

Abcam Semi-Annual Data
	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Jun22	Dec22	Jun23
EV-to-EBITDA	Get a 7-Day Free Trial															-	-	-	70.33	-

Competitive Comparison of Abcam's EV-to-EBITDA

For the Biotechnology subindustry, Abcam's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abcam's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abcam's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Abcam's EV-to-EBITDA falls into.

Abcam EV-to-EBITDA Calculation

Abcam's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	5294.549	/	78.183
	=	67.72

Abcam's current Enterprise Value is $5,294.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abcam's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $78.2 Mil.

Abcam (OTCPK:ABCZF) EV-to-EBITDA Explanation

Abcam's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	22.25	/	0.015
	=	1,483.33

Abcam's share price for today is $22.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abcam's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.015.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Abcam EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Abcam's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Abcam (ABCZF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abcam PLC (OTCPK:ABCZF) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Discovery Drive, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AX

Website

https://www.abcam.com

Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.